Phase I Combination Ixabepilone + Cisplatin

Study summary

The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedIxabepilone and Cisplatin

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 28, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?R-Pharm

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: R-Pharm
Interventions being studied: Drug: Ixabepilone; Drug: Cisplatin; Drug: Ixabepilone; Drug: Cisplatin

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Escalation Phase Subjects: Primary solid tumor not curable by local measures such as surgery, radiation
Men and women age ≥ 18 Exclusion:
More than 2 prior chemotherapy containing regimens for metastatic disease
No prior exposure to cisplatin or ixabepilone Expansion Phase Subjects: Advanced Non-small cell lung cancer Inclusion Criteria:
Men and women age ≥ 18 Exclusion:
No prior chemotherapy-containing regimen for metastatic disease
No prior exposure to cisplatin or ixabepilone

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Georgetown University Medical CenterWashington D.C., District of Columbia
The Cancer Institute Of New JerseyNew Brunswick, New Jersey
Penn State Milton S. Hershey Medical CenterHershey, Pennsylvania
Local InstitutionLucca
Local InstitutionMeldola (Fc)
Local InstitutionRimini
Local InstitutionViterbo

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 28, 2020. Always confirm current availability with the study team.

View original record ↗